Value Of Myocardial Perfusion Scintigraphy Research Articles

Prognostic implication of myocardial perfusion and contractile reserve in end-stage renal disease: A direct comparison of myocardial perfusion scintigraphy and dobutamine stress echocardiography

BackgroundWe aimed to compare the prognostic value of myocardial perfusion scintigraphy (MPS) and dobutamine stress echocardiography (DSE) in patients with end-stage renal disease (ESRD) without known coronary artery disease. MethodsTwo-hundred twenty-nine ESRD patients who applied for kidney transplantation at our centre were prospectively evaluated by MPS and DSE. The primary endpoint was a composite of myocardial infarction (MI) or all-cause mortality. The secondary endpoint included MI or coronary revascularization (CR) not triggered by MPS or DSE at baseline. ResultsMPS detected reversible ischemia in 31 patients (13.5%) and fixed perfusion defects in 13 (5.7%) patients. DSE discovered stress-induced wall motion abnormalities (WMAs) in 28 (12.2%) and at rest in 18 (7.9%) patients. MPS and DSE results agreed in 85.6% regarding reversible defects (κ = 0.358; P < .001) and in 90.8% regarding fixed defects (κ = 0.275; P < .001). Coronary angiography detected relevant stenosis > 50% in only 15 of 38 patients (39.5%) with pathological findings in MPS and/or DSE. At a median follow-up of 8 years and 10 months, the primary endpoint occurred in 70 patients (30.6%) and the secondary endpoint in 24 patients (10.5%). The adjusted Cox hazard ratios (HRs) for the primary endpoint were 1.77 (95% CI 1.02-3.08; P = .043) for perfusion defects in MPS and 1.36 (95% CI 0.78-2.37; P = ns) for WMA in DSE. The secondary endpoint was significantly correlated with the findings of both modalities, MPS (HR 3.21; 95% CI 1.35-7.61; P = .008) and DSE (HR 2.67; 95% CI 1.15-6.20; P = .022). ConclusionPerfusion defects in MPS are a stronger determinant of all-cause mortality, MI and the need for future CR compared with WMAs in DSE. Given the complementary functional information provided by MPS vs DSE, results are sometimes contradictory, which may indicate differences in the underlying pathophysiology.

Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial

BackgroundThe Basel Asymptomatic High-Risk Diabetics’ Outcome Trial (BARDOT) demonstrated that asymptomatic diabetic patients with an abnormal myocardial perfusion scintigraphy (MPS) were at increased risk of major adverse cardiovascular events (MACEs) at 2-year follow-up. It remains unclear whether this finding holds true even for a longer follow-up.MethodsFour hundred patients with type 2 diabetes, neither history nor symptoms of coronary artery disease (CAD), were evaluated clinically and with MPS. Patients were followed up for 5 years. Major adverse cardiovascular events (MACEs) were defined as all-cause death, myocardial infarction, or late coronary revascularization.ResultsAt baseline, an abnormal MPS (SSS ≥ 4 or SDS ≥ 2) was found in 87 of 400 patients (22%). MACE within 5 years occurred in 14 patients with abnormal MPS (16.1%) and in 22 with normal scan (1.7%), p = 0.009; 15 deaths were recorded. Patients with completely normal MPS (SSS and SDS = 0) had lower rates of MACEs than patients with abnormal scans (2.5% vs. 7.0%, p = 0.032). Patients with abnormal MPS who had undergone revascularization had a lower mortality rate and a better event-free survival from MI and revascularization than patients with abnormal MPS who had either undergone medical therapy only or could not be revascularized (p = 0.002).ConclusionsMPS may have prognostic value in asymptomatic diabetic patients at high cardiovascular risk over a follow-up period of 5 years. Patients with completely normal MPS have a low event rate and may not need retesting within 5 years. Patients with an abnormal MPS have higher event rates and may benefit from a combined medical and revascularization approach.

Prognostic value of myocardial perfusion scintigraphy in diabetic patients and without coronary lesion

ObjectiveTo determine the prognostic value of myocardial perfusion scintigraphy-gated SPECT in patients with diabetes mellitus and without obstructive coronary artery disease. Materials and methodsThis retrospective study included consecutive patients undergoing adenosine stress-rest myocardial perfusion imaging (MPI) by 99mTc-tetrofosmin between 2009 and 2011. The patients had diabetes mellitus and coronary angiography without significant coronary lesions. In total, 37 diabetic patients (female/male: 20/17; mean age: 65.2 (range: 40−78). 29 non-diabetic patients were included wich are matched with the group of diabetic patients with positive MPI. The group of non-diabetic patients had scintigraphy with myocardial ischemia and without angiographic lesions. A 36-month clinical follow-up was performed, and major cardiac events were recorded. ResultsIn 78.3% (29/37) of diabetic patients the scintigraphic study showed myocardial ischemia, while it was negative in the 21.7%. The cardiac event rate in both groups was 6%. In diabetics with a myocardial perfusion study with myocardial ischemia, there were 3 major cardiac events. In diabetic patients with negative study had no cardiac event. In the non-diabetic control group the cardiac events rate was 3.4% (1/29). ConclusionIn diabetic patients without obstructive coronary disease, myocardial perfusion study can be predictor of cardiac events. A negative study can be an indicator of a better cardiovascular prognosis.

Myocardial perfusion scintigraphy for risk stratification of patients with coronary artery disease: the AMICO registry

Abstract Funding Acknowledgements Type of funding sources: None. onbehalf AMICO registry Background. Clinical evidence promotes therapy titration based on patient risk stratification in coronary artery disease (CAD). Purpose. We assessed the prognostic value of myocardial perfusion scintigraphy (MPS) with cadmium-zinc-telluride in addition to clinical and coronary anatomy analysis. Methods and Results. We prospectively enrolled 1464 patients (26% females, 69.5 ± 10.4 years) referred for stress-rest MPS. All the patients underwent invasive coronary angiography (1171, 80%) or coronary computed tomography angiography (293, 20%). We defined a composite endpoint of cardiovascular death and non-fatal MI. After a median follow-up of 3.5 years (interquartile range 2 – 6 years), we observed 127 events (Table). Summed stress score (SSS) had the highest accuracy in predicting primary endpoint with a ROC-derived cut-off of SSS &amp;gt; 8 (&amp;gt;10% myocardium). SSS &amp;gt; 8 portended the lowest survival probability at Kaplan–Meier analysis (p &amp;lt; 0.0001; Figure A). The Cox-regression analysis indicated SSS as an independent predictor of the composite endpoint, along with fasting blood glucose and total cholesterol and contrary to coronary anatomy parameters. Patients with SSS &amp;gt; 8 treated with optimal medical therapy (OMT) had the largest area of necrosis, the lower ischemic burden, the most compromised LV systo-diastolic function and the highest LV mass, but received a less aggressive treatment in comparison to early revascularized patients. Survival analysis revealed patients with SSS ≤ 8 had the greater freedom from events, irrespective of the treatment strategy, while the group with SSS &amp;gt; 8 and OMT had the worst outcome, followed by patients with SSS &amp;gt; 8 and early revascolarization (log-rank test: all p &amp;lt; 0.0001). Plotting the estimates from proportional-hazard modelling against SSS (reference level: SSS = 4) shows a risk curve for the primary endpoint that increase for SSS &amp;gt; 4 and reach a plateau for values &amp;gt;12 (Figure B). Conclusion. The extension of stress perfusion abnormalities constitutes a robust independent predictor of future adverse events after adjustment for multiple clinical parameters and coronary anatomy analysis. MPS could help refine risk stratification of patients with known or suspected CAD. Primary and secondary endpoints Variable Total population (n = 1464) SSS &amp;gt; 8 (n = 591) SSS ≤ 8 (n = 873) Hazard Ratio (95% CI)* P-value* Primary endpoint 127 (9) 85 (14) 42 (5) 3.25 (2.25 - 4.70) &amp;lt;0.0001 Cardiovascular death 50 (3) 37 (6) 13 (1) 4.53 (2.41 - 8.51) &amp;lt;0.0001 Non-fatal MI 84 (6) 53 (9) 31 (4) 2.71 (1.75 - 4.22) &amp;lt;0.0001 *The hazard ratio is for the SSS &amp;gt; 8 group as compared with the summed stress score (SSS)≤8 group, and P-values were calculated by the log-rank test and are unadjusted for multiple variables. Abstract Figure

Myocardial perfusion scintigraphy for risk stratification of patients with coronary artery disease: the AMICO registry.

We assessed the prognostic value of myocardial perfusion scintigraphy (MPS) with cadmium-zinc-telluride in addition to clinical and coronary anatomy analysis. We prospectively enrolled 1464 patients (26% females, 69.5 ± 10.4 years) referred for stress-rest MPS. All the patients underwent invasive coronary angiography (1171, 80%) or coronary computed tomography angiography (293, 20%). We defined a composite endpoint of cardiovascular death and non-fatal MI. After an 8-year follow-up, summed stress score (SSS) had the highest accuracy in predicting primary endpoint with a ROC-derived cut-off of SSS >8 (>10% myocardium). SSS >8 portended the lowest survival probability at Kaplan-Meier analysis (P < 0.0001 for the composite endpoint and individual components). The Cox-regression analysis indicated SSS as an independent predictor of the composite endpoint, along with fasting blood glucose and total cholesterol and contrary to coronary anatomy parameters. Patients with SSS >8 treated with optimal medical therapy (OMT) had the largest area of necrosis, the lower ischaemic burden, the most compromised LV systo-diastolic function and the highest LV mass, but received a less aggressive treatment in comparison to early revascularized patients. Survival analysis revealed patients with SSS ≤8 had the greater freedom from events, irrespective of the treatment strategy, while the group with SSS >8 and OMT had the worst outcome, followed by patients with SSS >8 and early revascularization (log-rank test: all P < 0.0001). MPS-SSS constitutes a strong independent predictor of future adverse events after adjustment for multiple clinical parameters and coronary angiography. In particular, MPS could help risk stratification of patients who did not undergo early revascularization.

The diagnostic accuracy of myocardial perfusion scintigraphy in athletes with abnormal exercise test results.

Background Previous studies revealed a relatively high prevalence of electrocardiographic findings indicative for myocardial ischemia in asymptomatic athletes undergoing pre-participation screening. Myocardial perfusion scintigraphy is generally considered a valuable diagnostic and prognostic modality and often used for further diagnostic evaluation in these subjects. However, data on the diagnostic accuracy of myocardial perfusion scintigraphy in athletes are scarce. Objectives The main purpose of this study was to investigate the positive predictive value of myocardial perfusion scintigraphy for detection of coronary artery disease in asymptomatic athletes with abnormal exercise testing results during pre-participation screening. The secondary aim was to evaluate the prognostic value of myocardial perfusion scintigraphy. Methods Electronic charts of asymptomatic athletes who underwent myocardial perfusion scintigraphy following an abnormal exercise testing were retrospectively reviewed. Myocardial perfusion scintigraphy and exercise testing studies were revised. Athlete characteristics and cardiovascular risk factors were evaluated. Results One hundred and forty-three athletes were included. 29 athletes (20%) showed concordant abnormal exercise testing and myocardial perfusion scintigraphy results. Coronary imaging was performed in 20 of these 29 athletes. Four athletes showed significant coronary artery disease (positive predictive value = 20%). The positive predictive value increased to 33% when athletes were selected who should have undergone exercise testing according to the guideline recommendations. During a mean follow-up interval of 4.7 ± 2.2 years, eight cardiac events occurred. Athletes with an abnormal myocardial perfusion scintigraphy result had a fourfold increased risk at a future cardiac event (2.9%/year versus 0.75%/year, p = 0.031). Conclusions The positive predictive value of myocardial perfusion scintigraphy for the detection of significant coronary artery disease in asymptomatic athletes with a positive exercise testing result is low, even in a selection of athletes with a relatively high cardiovascular risk. Although an abnormal myocardial perfusion scintigraphy result was associated with a fourfold higher annual event rate, the absolute annual event rate in this group was still low. Efforts should be made to develop better diagnostic strategies to evaluate asymptomatic athletes with abnormal exercise testing results during pre-participation screening.

PW321 Value of myocardial perfusion scintigraphy in the assessment of patients without cardiac symptoms

PW321 Value of myocardial perfusion scintigraphy in the assessment of patients without cardiac symptoms

Prognostic value of myocardial perfusion scintigraphy in elderly patients with hypertension: a 10-year follow-up analysis

The aim of the study was to assess the role of myocardial perfusion scintigraphy (MPS) in the prediction of future cardiac events in elderly hypertensive patients and to investigate if its prognostic value is maintained during a 10-year follow-up period. A total of 229 consecutive patients ≥ 65 years old (range 65-88 years) with arterial hypertension, who were referred to our institution for stress/rest (99m)Tc-sestamibi MPS between January 2000 and November 2001, were followed up for 10-12 years. Cardiac death, myocardial infarction and a coronary revascularization procedure were considered as events. Survival curves were computed by the Kaplan-Meier method. A stepwise Cox proportional hazards analysis was used to identify predictors of events. Follow-up was completed in 221 (96.5 %) patients; 26 patients experienced cardiac death, 29 myocardial infarction and 51 coronary revascularization. Annual event rates for cardiac death, cardiac death/myocardial infarction and cardiac death/myocardial infarction/coronary revascularization were, respectively, 0, 0.2 and 0.4 % for patients with a normal scan and 1.5, 3.0 and 5.3 % after an abnormal MPS. Event-free survival was significantly different according to extent and severity of perfusion defects (all p < 0.01). An increase in global chi-square in predicting cardiac events occurred when MPS data were added to pre-scan information (from 47.28 to 88.87; p < 0.001). MPS provides incremental prognostic information for the prediction of cardiac events in elderly patients with hypertension. Subjects with a normal scan have an excellent 10-year outcome, and the risk of experiencing a cardiac event increases with extension and severity of stress perfusion defect.

The prognostic value of myocardial perfusion scintigraphy compared to coronary angiography in women with positive stress test results

Modern diagnostic strategy in coronary artery disease (CAD) makes it necessary not only to establish a diagnosis but also to assess the cardiovascular risk. It is not clear which strategy should be followed in the case of women with positive ECG stress test results to assess prognosis and start appropriate diagnostics and treatment.The aim of the study was to assess the prognostic value of myocardial perfusion scintigraphy in comparison with coronary angiography in women suspected of CAD and with positive ECG stress test results. The study population comprised 115 women (mean age 58.08 ± 8.8 years) suspected of CAD, with a history of chest pain and positive stress test results, who underwent myocardial perfusion scintigraphy. In 58 women coronary angiography was performed as the next step of the diagnostic procedure. All the patients were interviewed and had a physical examination, including the assessment of the cardiovascular risk in accordance with the SCORE (Systematic Coronary Risk Evaluation) scale and the probability of CAD (POST-TEST) in accordance with the ESC guidelines. The gated single photon emission computed tomography (GSPECT) with Tc-99m-MIBI was considered positive if moderate perfusion changes were observed in at least two segments or severe reversible perfusion disorders were found, regardless of the number of involved segments.The degree of coronary stenosis was assessed visually and changes greater than 50% stenosis of the luminal diameter were considered haemodynamically significant. The evaluation period covered 43.2 ± 30.8 months on average. The sensitivity of myocardial perfusion scintigraphy against cardiovascular events was 100% and the sensitivity of coronary angiography was 92.3%. The specificity was 93.1%and 88.9% respectively. The PPV of scintigraphy for cardiovascular events was 65% and of coronary angiography was 70.6%. The NPV was 100% and 97.6%respectively. The accuracy of myocardial perfusion scintigraphy for cardiovascular events was 93.9% and the accuracy of coronary angiography for cardiovascular events was 89.7%. The survival analysis confirmed the high prognostic value of SPECT and coronary angiography. However, if compared, myocardial perfusion scintigraphy was a better predictor of survival without cardiovascular events than coronary angiography was (c2 = 9.39, p < 0.01).The most important factors in assessing the cardiovascular risk in the study population included: positive result of myocardial perfusion scintigraphy, positive result of coronary angiography,and high SCORE and high POST-TEST values. Myocardial perfusion scintigraphy is superiorto coronary angiography in the prediction of necessary revascularisation procedures in women suspected of coronary artery disease and with positive stress test results.

Prognostic value of myocardial perfusion scintigraphy for patients suspected of and diagnosed with coronary artery disease

The prognostic value of myocardial perfusion scintigraphy (MPS) continues to attract interest and provoke discussions.This study was an attempt to investigate the methods. Determination of the prognostic value of MPS for patients suspected of and diagnosed with coronary artery disease (CAD). The study group included 215 patients, 134 males and 81 females, aged 21-66, mean age 48. Tc-99m-MIBI myocardial perfusion scintigraphy was performed and information concerning the diagnosis, aim of the examination, past coronary episodes, clinical condition, duration and type of complaints, concomitant diseases, test results, revascularisation procedures and pharmacological treatment was gathered. Further history of the patients was monitored throughout the observation period of 52 months on average. The patients were divided into the following two groups: Group I - suspected coronary artery disease: 124 patients aged 21-65,59 males and 65 females; Group II - diagnosed coronary artery disease: 91 patients aged 31-66, 75 males and 16 females diagnosed with CAD, including 39 s/p myocardial infarct, 31s/p infarct and revascularisation, 21 s/p revascularisation. The probability of CAD was calculated using the Diamond method for the patients suspected of CAD. The obtained results were examined in a statistical analysis. Normal MPS results were obtained for 94/124 patients suspected of CAD, 15/91 patients diagnosed with CAD,64/81 females and 45/134 males. In Group I, apart from pathological MPS results, reversible ischemia was determined in as many as 27/30 patients, and only 17/91 patients in Group II. No patients with normal MPS results suffered major cardiac events,only one of them underwent revascularisation. Major cardiac events occurred in the case of patients with pathological MPS results: Group I - 2 myocardial infarcts and 2 cardiac deaths,Group II - 3 infarcts and 10 cardiac deaths. Minor cardiac events, apart from one case, were also only observed in the case of patients with pathological MPS results: Group I - 10 revascularisations and one case of unstable CAD, Group II- 12 revascularisations and 7 cases of unstable CAD. Patients with normal MPS results and stenosis in coronary angioraphy suffered no cardiac events. Cardiac events occur mostly in the group with a medium and high risk of CAD and in the case of patients diagnosed with CAD. 1. Normal MPS results for patients suspected of or diagnosed with CAD: s/p infarct and/or CABG prognosticate a mild course of the disease, without or with a minimal number of cardiac events, also in a longer observation period.2. Pathological MPS results clearly imply a greater risk of cardiac events, and the number of events increases with the greater probability of CAD and with the patient's age. 3. Normal MPS results, even with significant stenosis in coronary angiography,prognosticate a low risk of cardiac events.

Prognostic value of myocardial perfusion scintigraphy for patients suspected of and diagnosed with coronary artery disease

Prognostic value of myocardial perfusion scintigraphy for patients suspected of and diagnosed with coronary artery disease

The prognostic value of myocardial perfusion scintigraphy compared to coronary angiography in women with positive stress test results

BACKGROUND: Modern diagnostic strategy in coronary arterydisease (CAD) makes it necessary not only to establish a diagnosisbut also to assess the cardiovascular risk. It is not clearwhich strategy should be followed in the case of women withpositive ECG stress test results to assess prognosis and startappropriate diagnostics and treatment.The aim of the study was to assess the prognostic value ofmyocardial perfusion scintigraphy in comparison with coronaryangiography in women suspected of CAD and with positive ECGstress test results. MATERIAL AND METHODS: The study population comprised115 women (mean age 58.08 ± 8.8 years) suspected of CAD, witha history of chest pain and positive stress test results, who underwent myocardial perfusion scintigraphy. In 58 women coronaryangiography was performed as the next step of the diagnosticprocedure. All the patients were interviewed and had a physicalexamination, including the assessment of the cardiovascularrisk in accordance with the SCORE (Systematic Coronary RiskEvaluation) scale and the probability of CAD (POST-TEST) inaccordance with the ESC guidelines. The gated single photonemission computed tomography (GSPECT) with Tc-99m-MIBIwas considered positive if moderate perfusion changes wereobserved in at least two segments or severe reversible perfusiondisorders were found, regardless of the number of involved segments.The degree of coronary stenosis was assessed visuallyand changes greater than 50% stenosis of the luminal diameterwere considered haemodynamically significant. RESULTS: The evaluation period covered 43.2 ± 30.8 monthson average. The sensitivity of myocardial perfusion scintigraphyagainst cardiovascular events was 100% and the sensitivity ofcoronary angiography was 92.3%. The specificity was 93.1%and 88.9% respectively.The PPV of scintigraphy for cardiovascular events was 65% and ofcoronary angiography was 70.6%. The NPV was 100% and 97.6%respectively. The accuracy of myocardial perfusion scintigraphy forcardiovascular events was 93.9% and the accuracy of coronaryangiography for cardiovascular events was 89.7%. The survivalanalysis confirmed the high prognostic value of SPECT and coronaryangiography. However, if compared, myocardial perfusionscintigraphy was a better predictor of survival without cardiovascularevents than coronary angiography was (c2 = 9.39, p &lt; 0.01).The most important factors in assessing the cardiovascular riskin the study population included: positive result of myocardialperfusion scintigraphy, positive result of coronary angiography,and high SCORE and high POST-TEST values. CONCLUSIONS: Myocardial perfusion scintigraphy is superiorto coronary angiography in the prediction of necessary revascularisation procedures in women suspected of coronary arterydisease and with positive stress test results.

Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates

A cardiac evaluation before orthotopic liver transplantation (OLT) is imperative. Previous investigations have demonstrated that mild to moderate reversible perfusion defects on myocardial perfusion scintigraphy (MPS) in general are associated with a low risk for perioperative cardiac events. The objective of this study was to assess any perfusion defects in consecutive patients with chronic liver disease who were undergoing OLT. OLT candidates underwent extensive cardiovascular screening that included, among other methods, MPS. Patients who had no contraindications for surgery and underwent OLT were followed up. The occurrence and risk of complications and mortality were compared in 3 groups of patients: patients with normal MPS results, patients with any reversible defect, and patients with a fixed perfusion defect on MPS. In all, 156 subsequent patients underwent OLT. One or more reversible segmental perfusion defects on MPS were present in 14 patients (<3 segments, n = 12; 3 segments without obstructive coronary artery disease, n = 2). The risk of complications did not differ significantly between patients with normal MPS findings and patients with a reversible perfusion defect (odds ratio = 3.04, 95% confidence interval = 0.65-14.26, P = 0.16), although the study was not sufficiently powered to show a difference. The presence of 1 or more reversible defects on MPS was significantly associated with an increased incidence of all-cause 1-year mortality (hazard ratio = 3.17, 95% confidence interval = 1.02-9.83, P = 0.046). No significant difference in the outcomes of patients with normal MPS findings and patients with a fixed defect on MPS was found; the study was, however, not adequately powered to do so. In conclusion, the results of this small cohort study indicate that patients with mild to moderate reversible perfusion defects on MPS may have inferior survival characteristics in comparison with patients with normal MPS results. A prospective, adequately powered study is required to confirm the results of this study.

Hat die Myokardszintigrafie heute noch einen Stellenwert in der Kardiologie?

Myocardial perfusion scintigraphy evolved into the modality of choice regarding non-invasive imaging for the presence of obstructive coronary artery disease (CAD) in patients with clinically suspected or already known CAD in the 80ies and 90ies. However, new non-invasive imaging modalities such as cardiovascular magnetic resonance imaging (CMR) have been established in the last years and are challenging the clinical predominance of myocardial perfusion scintigraphy in evaluating myocardial ischemia and thereby constituting the gatekeeper to invasive cardiac catheterization. In particular, CMR-based methods (comprising dobutamine-stress-CMR and adenosine-perfusion-CMR) offer at least equal diagnostic accuracy compared to conventional myocardial perfusion scintigraphy while having less side effects (e. g. no radiation burden). Therefore, the present and future clinical value of myocardial perfusion scintigraphy may become seriously questioned. In this review, the present clinical value of myocardial perfusion scintigraphy is critically assessed in comparison to CMR-based imaging modalities.

Prognostic value of myocardial perfusion scintigraphy in type 2 diabetic patients with mild, stable angina pectoris

AimTo determine the prognostic value of reversible myocardial perfusion defects on myocardial perfusion scintigraphy (MPS) in patients with type 2 diabetes mellitus and mild anginal complaints. Methods and resultsIn the MERIDIAN trial, patients with diabetes mellitus type 2, stable, mild anginal symptoms (Canadian Cardiovascular Society classification (CCS) I-II/IV) and reversible perfusion defects were randomized to either continued pharmacological treatment or early invasive treatment. In this sub analysis, the severity of the myocardial perfusion defect was related to the occurrence of cardiac death and non-fatal myocardial infarction, in 319 patients (63% male, 65 ± 9 years). During follow-up (2.2 ± 0.6 years), 14 patients had a cardiac event: 3 in 171 patients without myocardial ischemia and 11 in 148 patients with myocardial ischemia. Annual event rates rose from 0.8% to 5.8% with increasing severity of myocardial ischemia. Multivariable analysis identified the presence of severe myocardial ischemia (hazard ratio (HR) 5.45, 95%CI 1.89-15.71) and insulin use (HR 4.00, 95%CI 1.25-12.75) as independent predictors of cardiac events. ConclusionsType 2 diabetics with mild anginal symptoms with no or moderate myocardial ischemia have a low annual cardiac event rate. In patients with severe myocardial ischemia event rate increased 3-6 fold.

Prediction of Cardiac Events in Patients Having Left Bundle-Branch Block with/without Chest Pain Using Dipyridamole Technetium-99m-Sestamibi Myocardial Perfusion Imaging

Objective: To determine the prognostic value of myocardial perfusion scintigraphy with dipyridamole stress in patients with preexisting left bundle-branch block (LBBB) with or without chest pain. Subjects and Methods: Seventy-six patients, mean age 53 ± 10 years, with preexisting LBBB underwent technetium-99m-sestamibi perfusion imaging with dipyridamole infusion protocol (0.56 mg/kg). Stress and rest single photon emission computed tomography (SPECT) images were interpreted by consensus of 2 experienced nuclear medicine physicians and classified as low-risk scans (normal myocardial perfusion scan, small reversible/small fixed defect) and high-risk scans (large, severe, fixed or reversible defect and dilated left ventricle cavity). The patients were followed up for 24 ± 8 months and occurrences of hard cardiac events (infarction or cardiac death) were noted. Results: Of the 76 patients, 52 (68%) had low-risk scans and the remaining 24 (32%) had high-risk scans. In the low-risk group, 1 (1.9%) cardiac death and 2 (3.8%) cases of nonfatal myocardial infarction occurred, while in the high-risk group, 5 (20.8%) suffered cardiac death, and 3 (12.5%) nonfatal myocardial infarction. Overall survival rate was 98.1% in the low-risk group compared with 79.2% in the high-risk group with a significant difference of p = 0.034. Negative predictive value of normal myocardial perfusion scintigraphy for the occurrence of death was 100%. No significant difference in survival rate among patients with or without chest pain (p = 0.31) was observed. Conclusions: Myocardial perfusion imaging with dipyridamole provided important prognostic information in patients with LBBB; it was useful in stratifying the patients according to cardiovascular morbidity and mortality, and would thus allow the clinician to provide early treatment especially in the high-risk category.

Long-term prognostic value of dobutamine stress 99mTc-sestamibi SPECT: single-center experience with 8-year follow-up.

To determine the long-term prognostic value of dobutamine stress technetium 99m (99mTc)-labeled sestamibi single photon emission computed tomography (SPECT) in patients with limited exercise capacity. Clinical data and SPECT results were analyzed in 531 consecutive patients. Follow-up was successful in 528 (99.4%) patients; 55 underwent early revascularization and were excluded. Normal or abnormal findings were considered in the absence or presence of fixed and/or reversible perfusion defects. A summed stress score was calculated to estimate the extent and severity of perfusion defects. Univariate and multivariate Cox proportional hazards regression models were used to identify independent predictors of late cardiac events. The incremental value of myocardial perfusion scintigraphy over clinical variables in predicting events was determined according to two models. The probability of survival was calculated by using the Kaplan-Meier method. Findings were abnormal in 312 patients. During 8.0 years +/- 1.5 of follow-up (range, 4.5-10.6 years), cardiac death occurred in 67 patients (total deaths, 165); nonfatal myocardial infarction, in 34; and late revascularization, in 49. The annual rates for cardiac death, cardiac death or infarction, and all events were 0.9%, 1.2%, and 1.5%, respectively, after normal findings and 2.7%, 3.4%, and 4.4%, respectively, after abnormal findings (P <.05). In a multivariable Cox proportional hazards model, not only an abnormal finding but also the summed stress score provided incremental prognostic information in addition to clinical data. The hazard ratio for cardiac death was 1.09 (95% CI: 1.01, 1.18) per 1-unit increment of the summed stress score. The incremental prognostic value of dobutamine stress 99mTc-sestamibi SPECT over clinical data was maintained over an 8-year follow-up in patients with limited exercise capacity.

The prognostic value of myocardial perfusion scintigraphy: investigators, are you (mis)leading us?

The prognostic value of myocardial perfusion scintigraphy: investigators, are you (mis)leading us?

Incremental value of myocardial perfusion scintigraphy in prognosis and outcomes of patients with coronary artery disease.

The concept of incremental value in prognosis and outcome of patients with coronary artery disease is important to the field of noninvasive imaging. Because these tests are expensive, they should be held to the standard of demonstrating a statistical improvement over the information provided by clinical assessment and treadmill testing. Responding to the demand for cost-effective applications of myocardial perfusion scintigraphy, a large amount of research has recently been devoted to defining specific patient subsets in which incremental value exists for scintigraphy. Subsets thus far demonstrated to benefit incrementally include those men and women referred for possible coronary artery disease, with known coronary artery disease, and after percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, unstable angina, or recent infarction. Incremental cost savings also apply to these subsets except for patients with normal ECGs at rest and less than 15% likelihood for significant coronary artery disease.

The value of myocardial perfusion scintigraphy (MPS) in angiographically proven coronary artery disease (CAD)

The value of myocardial perfusion scintigraphy (MPS) in angiographically proven coronary artery disease (CAD)